- Biomarker-Guided ICI Therapy Provides Greater Benefit in Cancer Patients
- Low Immunity Against COVID-19 Omicron Variants Despite 3 Vaccine Doses in Hematologic Malignancies
- Precision Medicine in Severe Asthma Predicts Lack of Benefit From Biologics
- Patients With COPD on Triple vs Dual Therapy Have 7% Lower Exacerbation Risk
- Daylight Saving Time to Standard Time Transition Tied to Sleep Disorder Symptoms
- Risk Factors for Late-Onset P jirovecii Pneumonia After Liver Transplantation
- FDA Approves Xacduro for Difficult-to-Treat Bacterial Pneumonia
- Adverse Pregnancy Outcomes Increase Stroke Risk at an Earlier Age
- FDA Approves Extended-Release Injection for Opioid Use Disorder
- Regular Physical Activity Tied to Higher Pain Tolerance
- Predictors/Trajectories of Depressive Symptoms in Asthma, From Youth to Adulthood
- Elexacaftor/Tezacaftor/Ivacaftor Safe, Well Tolerated in Pediatric CF
Clinical Tools
Powered by
Powered by 
Relapse and Mortality Characteristics Identified for Adolescent Acquired Thrombotic Thrombocytopenic Purpura
Racial, Ethnic Inequities Identified in Opioid Access for Patients Dying of Cancer
Long COVID Explored in University Settings
Mortality Similar With Torsemide, Furosemide for Patients Hospitalized With Heart Failure
Jaypirca Approved for Relapsed/Refractory Mantle Cell Lymphoma
